Irinotecan Amarox (Irinotecan Hydrochloride Trihydrate)

• Irinotecan Amarox is a topoisomerase I inhibitor used in colorectal cancer chemotherapy.
• Metastatic colorectal cancer: contributes to prolonged overall survival and disease stabilization when combined with other cytotoxic agents.
• Advanced colorectal cancer: achieves tumor size reduction and symptomatic improvement as part of first‑line or second‑line chemotherapy regimens.
• Colorectal adenocarcinoma with unresectable lesions: facilitates down‑staging of tumors to enable potential surgical intervention in selected patients.
• Rectal cancer with distant metastasis: offers systemic disease control alongside radiotherapy in multidisciplinary approaches.

• After intravenous infusion, Irinotecan is converted by hepatic carboxylesterases to the active metabolite SN‑38. SN‑38 binds to the DNA‑topoisomerase I complex, preventing relegation of single‑strand breaks during DNA replication. This results in accumulation of DNA damage, inhibition of tumor cell proliferation, and ultimately cell death in rapidly dividing cancer cells. The effect is selective for cells with high replication rates, making it particularly effective against malignant tissue.

Irinotecan therapy is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Diarrhea: often severe and may require antidiarrheal medication.
• Nausea and vomiting: may be managed with standard antiemetics.
• Neutropenia: decreased white blood cell count increasing infection risk.
• Alopecia: hair loss that is usually reversible after treatment.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophil count requiring immediate medical attention.
• Severe colitis or intestinal perforation: life‑threatening complications of diarrhea.
• Elevated liver enzymes: indicating hepatic toxicity that may necessitate dose adjustment.

Prior to initiating Irinotecan Amarox, clinicians should observe several safety measures to minimize toxicity.

• Baseline blood counts: obtain complete blood count to assess neutrophil levels before treatment.
• Liver function monitoring: evaluate hepatic enzymes regularly because metabolism depends on liver activity.
• Hydration status: ensure adequate fluid intake to reduce risk of severe diarrhea.
• Concomitant myelosuppressive drugs: avoid or adjust doses of other agents that suppress bone marrow.
• CYP3A4 and UGT1A1 interactions: review patient medications for strong inhibitors or inducers that affect Irinotecan metabolism.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the product.

Irinotecan may interact with other medicines, altering its efficacy or increasing toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise SN‑38 levels and heighten toxicity.
• UGT1A1 inhibitors (e.g., atazanavir, indinavir): may reduce SN‑38 clearance leading to severe neutropenia.
• Concurrent myelosuppressive chemotherapy: increases risk of profound bone‑marrow suppression.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower drug exposure and reduce effectiveness.
• Warfarin: Irinotecan can affect anticoagulation control, requiring INR monitoring.
• Diuretics: may exacerbate dehydration from diarrhea, necessitating fluid balance assessment.